Two patents currently held, every record listed here
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next US patent term in the LSI Financing 1 Designated Activity Company portfolio ends in Jan 2031. from the record
Of the 2 now held by other companies, 2 name LSI Braf Sub LLC as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2031
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2013 to 2031.
US 8,791,265
Sulfonamido Derivatives of 3,4-Diarylpyrazoles as Protein Kinase Inhibitors
Jan 19, 2031
US 9,114,137
Derivatives of Pyrazolophenyl-Benzenesulfonamide Compounds and Use Thereof as Antitumor Agents
no later than Nov 21, 2031
20172021202520292031
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
Every computed term in this portfolio is shown above.Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jan 2031 · High confidence
Also notable
Ends no later than Nov 2031 · Medium confidence
Sulfonamido Derivatives of 3,4-Diarylpyrazoles as Protein Kinase Inhibitors
US 8,791,265
Renewed at every maintenance window since the 2014 grant; no more fees are due before its term ends in 2031.
Derivatives of Pyrazolophenyl-Benzenesulfonamide Compounds and Use Thereof as Antitumor Agents
US 9,114,137
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2031. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Formerly held, still cited
Notable
Ends no later than Jul 2029 · Low confidence
Cited by 17 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by LSI Braf Sub, LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 25, 2027The maintenance fee for Derivatives of Pyrazolophenyl-Benzenesulfonamide Compounds and Use Thereof as Antitumor Agents (US 9,114,137) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,791,265 | Sulfonamido Derivatives of 3,4-Diarylpyrazoles as Protein Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 9,114,137 | Derivatives of Pyrazolophenyl-Benzenesulfonamide Compounds and Use Thereof as Antitumor Agents In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 2: 2 patents in force now held by others. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed